Does holding at 12.5 mg for eight weeks before escalating reduce constipation?

Stated plainly: 12.5 mg · eight weeks · constipation.

The empirical answer seems settled. The explanation does not.

If the honest answer is that nobody knows, I would rather hear that than a plausible story.

What is the causal chain, and where does it stop being established?

eight weeks at 12.5 mg is 56 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 12.5 mg back by 56 days. Whether that reduces constipation depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 12.5 mg is 12.5 mg on day 1 and on day 56. A symptom driven by the rate of change has 56 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot constipation against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Hold rather than escalate while symptoms are active. Always.

Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

More usefully, holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

A schedule described here is a published schedule for a licensed product and is not a recommendation.

The top of the schedule is not the target. The working dose is.

The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.

Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.

The caveat is that titration decisions belong with a clinician who knows what else is on board.

Slower costs time and nothing else. The ceiling is the same.

edited 4 Oct 2024 by forty_units — added the placebo-arm figures

The initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.

Stepping back is a normal adjustment, not a failure.

This is the single most consequential controllable variable in the whole experience, and people routinely rush it.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.

Four half-lives between steps, minimum. Work it out for your agent.